These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 12772201)
1. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. Iguchi C; Nio Y; Itakura M J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
3. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302 [TBL] [Abstract][Full Text] [Related]
4. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer. Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475 [TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466 [TBL] [Abstract][Full Text] [Related]
7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704 [TBL] [Abstract][Full Text] [Related]
8. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946 [TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of resectable breast cancer: a report of 6 263 cases]. Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535 [TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205 [TBL] [Abstract][Full Text] [Related]
11. Predicting likelihood of having four or more positive nodes in patient with sentinel lymph node-positive breast cancer: a nomogram validation study. Unal B; Gur AS; Beriwal S; Tang G; Johnson R; Ahrendt G; Bonaventura M; Soran A Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1035-40. PubMed ID: 19327916 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Harrell JC; Dye WW; Allred DC; Jedlicka P; Spoelstra NS; Sartorius CA; Horwitz KB Cancer Res; 2006 Sep; 66(18):9308-15. PubMed ID: 16982776 [TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189 [TBL] [Abstract][Full Text] [Related]
14. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526 [TBL] [Abstract][Full Text] [Related]
15. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients]. Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632 [TBL] [Abstract][Full Text] [Related]
16. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335 [TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156 [TBL] [Abstract][Full Text] [Related]
19. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer. Van den Eynden GG; Van der Auwera I; Van Laere SJ; Trinh XB; Colpaert CG; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA J Pathol; 2007 Sep; 213(1):56-64. PubMed ID: 17674348 [TBL] [Abstract][Full Text] [Related]
20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]